Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) fell 2.5% on Monday . The company traded as low as $1.11 and last traded at $1.14. 82,547 shares were traded during trading, an increase of 45% from the average session volume of 56,965 shares. The stock had previously closed at $1.17.
Wall Street Analyst Weigh In
Separately, HC Wainwright assumed coverage on Connect Biopharma in a report on Thursday, June 12th. They set a "buy" rating and a $7.00 price target for the company.
View Our Latest Research Report on CNTB
Connect Biopharma Stock Down 2.5%
The company has a 50 day moving average price of $0.87 and a 200 day moving average price of $0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.25 and a quick ratio of 10.25.
Connect Biopharma (NASDAQ:CNTB - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. As a group, equities research analysts expect that Connect Biopharma Holdings Limited Sponsored ADR will post -0.22 EPS for the current year.
Connect Biopharma Company Profile
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
